UNSPSC 51373322: Aspirin/caffeine/dihydrocodeine/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373322 Aspirin/caffeine/dihydrocodeine/promethazine is a Commodity code that in recent state and local procurement activity spans a broader range of pharmaceutical and health-related products than its narrow name suggests. The code does not appear in active use for its nominal product line; instead, recent solicitations tagged to this code involve naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local buying under the code includes county health departments procuring opioid-reversal agents and drug deactivation systems, state health agencies conducting market research on pharmacy benefit restructuring, and multistate cooperative purchasing alliances establishing contracts for generic pharmaceuticals and OTC inventory to serve government facilities and health plans across multiple participating jurisdictions.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing vehicles serving state procurement offices and subordinate local entities (Minnesota Department of Administration on behalf of MMCAP participants including Oregon). Recent opportunities span Florida, Texas, and the upper Midwest through multistate cooperative structures. Representative recent activity includes Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023); the Texas HHS Commission's Request for Information HHS0017013, posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription contracting outside traditional PBM channels; and Minnesota's MMCAP RFP S1070000015802, posted January 20, 2026, establishing multiple-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers with a March 26, 2026 proposal deadline and July 1, 2026 effective date.